RET/NTRK1 rearrangements in thyroid gland tumors of the papillary carcinoma family: Correlation with clinicopathological features

Italia Bongarzone, Paolo Vigneri, Luigi Mariani, Paola Collini, Silvana Pilotti, Marco A. Pierotti

Research output: Contribution to journalArticle

142 Citations (Scopus)

Abstract

The papillary carcinoma family (PCF) of thyroid tumors includes a wide variety of neoplastic entities regarded as well-differentiated, poorly differentiated, and undifferentiated papillary thyroid carcinomas. Recent studies have established the presence of alternative oncogenic rearrangements of the RET and NTRK1 genes in a consistent fraction (≤50%) of papillary thyroid tumors. RET oncogenic rearrangements are also very frequent (~60%) in Chernobyl radiation-associated papillary thyroid neoplasias, which show an increased aggressiveness in terms of pathological stage at disease onset. These observations prompted us to study the relationship between the presence or absence of RET and NTRK1 oncogenes and the clinicopathological features (age, sex, histopathology, and pTNMC2 staging) of 76 consecutive, non- radiation-related tumors of the PCF. As previously reported, statistical univariate analysis revealed a correlation between the combination of RET and NTRK1 (RET/NTRK1) positivity and young age of patients at diagnosis. In addition, a significant association was found between RET/NTRK1 positivity and locally advanced stage of disease at presentation (pT4: P <0.015). The multivariate analysis confirmed that RET/NTRK1 activation parallels an unfavorable disease presentation, which may correlate with a less favorable disease outcome. Furthermore, within the PCF, the frequency of RET/NTRK1 positivity was not influenced by the different neoplastic subtypes or the tumor versus degree of differentiation.

Original languageEnglish
Pages (from-to)223-228
Number of pages6
JournalClinical Cancer Research
Volume4
Issue number1
Publication statusPublished - Jan 1998

Fingerprint

Papillary Carcinoma
Thyroid Gland
Neoplasms
Radiation
Oncogenes
Multivariate Analysis
Genes
Papillary Thyroid cancer

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

RET/NTRK1 rearrangements in thyroid gland tumors of the papillary carcinoma family : Correlation with clinicopathological features. / Bongarzone, Italia; Vigneri, Paolo; Mariani, Luigi; Collini, Paola; Pilotti, Silvana; Pierotti, Marco A.

In: Clinical Cancer Research, Vol. 4, No. 1, 01.1998, p. 223-228.

Research output: Contribution to journalArticle

@article{4d9e0cc64e994acd8f3c19dbd836209c,
title = "RET/NTRK1 rearrangements in thyroid gland tumors of the papillary carcinoma family: Correlation with clinicopathological features",
abstract = "The papillary carcinoma family (PCF) of thyroid tumors includes a wide variety of neoplastic entities regarded as well-differentiated, poorly differentiated, and undifferentiated papillary thyroid carcinomas. Recent studies have established the presence of alternative oncogenic rearrangements of the RET and NTRK1 genes in a consistent fraction (≤50{\%}) of papillary thyroid tumors. RET oncogenic rearrangements are also very frequent (~60{\%}) in Chernobyl radiation-associated papillary thyroid neoplasias, which show an increased aggressiveness in terms of pathological stage at disease onset. These observations prompted us to study the relationship between the presence or absence of RET and NTRK1 oncogenes and the clinicopathological features (age, sex, histopathology, and pTNMC2 staging) of 76 consecutive, non- radiation-related tumors of the PCF. As previously reported, statistical univariate analysis revealed a correlation between the combination of RET and NTRK1 (RET/NTRK1) positivity and young age of patients at diagnosis. In addition, a significant association was found between RET/NTRK1 positivity and locally advanced stage of disease at presentation (pT4: P <0.015). The multivariate analysis confirmed that RET/NTRK1 activation parallels an unfavorable disease presentation, which may correlate with a less favorable disease outcome. Furthermore, within the PCF, the frequency of RET/NTRK1 positivity was not influenced by the different neoplastic subtypes or the tumor versus degree of differentiation.",
author = "Italia Bongarzone and Paolo Vigneri and Luigi Mariani and Paola Collini and Silvana Pilotti and Pierotti, {Marco A.}",
year = "1998",
month = "1",
language = "English",
volume = "4",
pages = "223--228",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "1",

}

TY - JOUR

T1 - RET/NTRK1 rearrangements in thyroid gland tumors of the papillary carcinoma family

T2 - Correlation with clinicopathological features

AU - Bongarzone, Italia

AU - Vigneri, Paolo

AU - Mariani, Luigi

AU - Collini, Paola

AU - Pilotti, Silvana

AU - Pierotti, Marco A.

PY - 1998/1

Y1 - 1998/1

N2 - The papillary carcinoma family (PCF) of thyroid tumors includes a wide variety of neoplastic entities regarded as well-differentiated, poorly differentiated, and undifferentiated papillary thyroid carcinomas. Recent studies have established the presence of alternative oncogenic rearrangements of the RET and NTRK1 genes in a consistent fraction (≤50%) of papillary thyroid tumors. RET oncogenic rearrangements are also very frequent (~60%) in Chernobyl radiation-associated papillary thyroid neoplasias, which show an increased aggressiveness in terms of pathological stage at disease onset. These observations prompted us to study the relationship between the presence or absence of RET and NTRK1 oncogenes and the clinicopathological features (age, sex, histopathology, and pTNMC2 staging) of 76 consecutive, non- radiation-related tumors of the PCF. As previously reported, statistical univariate analysis revealed a correlation between the combination of RET and NTRK1 (RET/NTRK1) positivity and young age of patients at diagnosis. In addition, a significant association was found between RET/NTRK1 positivity and locally advanced stage of disease at presentation (pT4: P <0.015). The multivariate analysis confirmed that RET/NTRK1 activation parallels an unfavorable disease presentation, which may correlate with a less favorable disease outcome. Furthermore, within the PCF, the frequency of RET/NTRK1 positivity was not influenced by the different neoplastic subtypes or the tumor versus degree of differentiation.

AB - The papillary carcinoma family (PCF) of thyroid tumors includes a wide variety of neoplastic entities regarded as well-differentiated, poorly differentiated, and undifferentiated papillary thyroid carcinomas. Recent studies have established the presence of alternative oncogenic rearrangements of the RET and NTRK1 genes in a consistent fraction (≤50%) of papillary thyroid tumors. RET oncogenic rearrangements are also very frequent (~60%) in Chernobyl radiation-associated papillary thyroid neoplasias, which show an increased aggressiveness in terms of pathological stage at disease onset. These observations prompted us to study the relationship between the presence or absence of RET and NTRK1 oncogenes and the clinicopathological features (age, sex, histopathology, and pTNMC2 staging) of 76 consecutive, non- radiation-related tumors of the PCF. As previously reported, statistical univariate analysis revealed a correlation between the combination of RET and NTRK1 (RET/NTRK1) positivity and young age of patients at diagnosis. In addition, a significant association was found between RET/NTRK1 positivity and locally advanced stage of disease at presentation (pT4: P <0.015). The multivariate analysis confirmed that RET/NTRK1 activation parallels an unfavorable disease presentation, which may correlate with a less favorable disease outcome. Furthermore, within the PCF, the frequency of RET/NTRK1 positivity was not influenced by the different neoplastic subtypes or the tumor versus degree of differentiation.

UR - http://www.scopus.com/inward/record.url?scp=0031931662&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031931662&partnerID=8YFLogxK

M3 - Article

C2 - 9516975

AN - SCOPUS:0031931662

VL - 4

SP - 223

EP - 228

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 1

ER -